Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>
SOURCE  Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 17, 2013) A million electric cars could be on ... with the help of research by the United States Department ... Waterloo. , Professor Zhongwei Chen is part of a team ... non-precious materials to replace the expensive platinum catalysts in fuel ... of fuel cells in vehicles is the cost of the ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 ExakTime, ... in North America, has introduced AccountLinx Plus, a ... payroll records between ExakTime’s software and industry-leading payroll ... software setup and keeps employee databases up-to-date in ... a business’ current payroll software, directly into ExakTime’s ...
(Date:6/18/2013)... FL (PRWEB) June 18, 2013 The human ... the skin as an important human body part. Similar to ... for in order to function, repair and grow. Recent reports ... vitamins and supplements, is just as important as other life ... supplements to aid in skin cell reproduction, increase the appearance ...
(Date:6/18/2013)... RegeneCure announced today the start of a ... (GBR) Dental Membrane as a bone stimulating aid for patients ... patients have a tooth replaced with a dental implant is ... Consequently there is often a need to support the implant ... bone substitute material, in turn, needs to be held in ...
Breaking Biology Technology:US and Canadian researchers drive towards cheaper fuel cells for electric cars 2ExakTime Introduces AccountLinx Plus 2Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3
... July 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), ... agreement to exclusively license seven cancer antigens from ... antigens specifically target breast, ovarian and prostate cancers. ... DepoVax(TM) delivery platform to develop DPX-0907, a therapeutic ...
... , , TAMPA, Fla., July 14 ... the research and development of cancer immunotherapies, announces that the first ... dendritic cell therapy. , , ... clinical trial testing the safety and efficacy of its immunotherapy on ...
... , , ... biotechnology company delivering breakthrough therapies in central nervous system ... the efficacy of the ketogenic compound AC-1202 (Axona(TM)) in ... completed double-blind, placebo-controlled trial in patients with mild-to-moderate Alzheimer,s ...
Cached Biology Technology:ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 2Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 3Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 4
(Date:6/19/2013)... paper published in the journal Polar Biology, researchers report using ... may be a new type of killer whale ( Orcinus ... unusual-looking killer whales stranded on a New Zealand beach and ... were also taken but it was almost 50 years before ... small white eye-patch and bulbous forehead, was documented alive in ...
(Date:6/19/2013)... Insulin is the most potent physiological anabolic agent ... and synthesis of lipids, protein and carbohydrates, and ... system. It also plays a major role in ... glucose is metabolized and removed from the blood ... precise molecular mechanisms by which insulin regulates glucose ...
(Date:6/19/2013)... the Midwest are expected to contribute to a very ... zone," according to a University of Michigan ecologist and ... one for the Chesapeake Bay. , The Gulf forecast, ... Atmospheric Administration, calls for an oxygen-depleted, or hypoxic, region ... place it among the 10 largest on record. , ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... plant,s defences and causes disease,by sneakily disabling the plant,s ... (4 December) in Current Biology . ... causes bacterial speck disease,in tomato plants. This bacterial invasion ... cause extensive and costly damage to,tomato crops, and researchers ...
... half of a person,s body mass consisting of skeletal ... those found in the limbs can result in ... kinesiology and community health professor Kimberly Huey, past research ... may be associated with reduced expression of certain pro-inflammatory ...
... earthquakes and destructive tsunamis over the past four years is ... warns an international group of earthquake researchers in their paper ... Nature . , The first of the recent great earthquakes, ... and destructive tsunami in living memory. The cause of ...
Cached Biology News:Red alert! How disease disables tomato plant's 'intruder alarm' 2Vitamin E shows possible promise in easing chronic inflammation 2Vitamin E shows possible promise in easing chronic inflammation 3September 2007 Sumatran earthquakes research findings 2September 2007 Sumatran earthquakes research findings 3
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
... Casein Kinase 1, active MW: 34.2kDa ... NaCl, 0.02% Brij-35, 1mM dithiothreitiol with ... data, refer to the Certificate of ... Purification: ammonium salt precipitation followed by ...
Supplemental reagent for annexin V assay....
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Biology Products: